Bacil Pharma (BOM:524516) Interest Expense: ₹0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524516 Bacil Pharma Ltd BOM:524516
27 GF Score
Price ₹13.23
View Full Analysis

What is Bacil Pharma Interest Expense?

Bacil Pharma BOM:524516 +5.00% 27 Interest Expense is ₹0.00 Mil as of Jun. 2026. GuruFocus rates BOM:524516 with a GF Score™ of 27/100.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Bacil Pharma's interest expense for the three months ended in Jun. 2026 was ₹ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Bacil Pharma's Operating Income for the three months ended in Jun. 2026 was ₹ -0.23 Mil. Bacil Pharma's Interest Expense for the three months ended in Jun. 2026 was ₹ 0.00 Mil. Bacil Pharma has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Bacil Pharma  (BOM:524516) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Bacil Pharma's Interest Expense for the three months ended in Jun. 2026 was ₹0.00 Mil. Its Operating Income for the three months ended in Jun. 2026 was ₹-0.23 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2026 was ₹0.00 Mil.

Bacil Pharma's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as

Bacil Pharma had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Bacil Pharma Ltd has no debt.

Bacil Pharma Interest Expense Historical Data

* Premium members only.

The historical data trend for Bacil Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bacil Pharma Interest Expense Chart

Bacil Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 0.00

Bacil Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:524516
27GF Score
Bacil Pharma Ltd BOM:524516
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bacil Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of ₹0.00 Mil mean?
Bacil Pharma (BOM:524516) has a Interest Expense of ₹0.00 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Bacil Pharma and its competitors.
Is Bacil Pharma's Interest Expense too high?
Bacil Pharma's current Interest Expense is ₹0.00 Mil. Overall, Bacil Pharma has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Bacil Pharma's Interest Expense compare to ZTS?
Bacil Pharma's Interest Expense of ₹0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Bacil Pharma and its competitors. Bacil Pharma's current Interest Expense is ₹0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bacil Pharma stock overvalued right now?
Bacil Pharma (BOM:524516) has a current Interest Expense of ₹0.00 Mil. The current Interest Expense is ₹0.00 Mil. Bacil Pharma's overall GF Score™ is 27/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Bacil Pharma (BOM:524516), the current Interest Expense is ₹0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bacil Pharma Business Description

Address Link Road, Office G2 & G3, Samarpan Complex, Opp Satam Wadi, Sahar P & T Colony, Chakala, Next to Mirador Hotel, Andheri East, Mumbai, MH, IND, 400099
Bacil Pharma Ltd is an Indian-based pharmaceutical company engaged in healthcare solutions, basically in the development, manufacturing, and distribution of a range of pharmaceutical products across therapeutic segments. operating in a single segment. The product of the company includes tablets, capsules, injectables, ointments, and specialty products.
27GF Score

Get the complete analysis for BOM:524516

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹13.23
Price